Pentobarbital
5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
Overview
Pentobarbital belongs to Depressants.
Effects
- Sedation, anxiety relief, drowsiness and, at higher doses, sleep. Disinhibition and a 'drunk' euphoria some seek recreationally.
- Slurred speech, poor coordination, impaired memory and judgement.
- With regular use: rapid tolerance, physical dependence, and a dangerous withdrawal (tremor, seizures) on stopping.
Dosing & duration
Oral, and by injection (IV/IM) or rectally: clinician-administered. Figures below are clinical context, NOT a recreational guide. Pentobarbital is used deliberately to end life and there is no safe recreational dose.. Pentobarbital's effect runs on a steep continuum from sedation to anaesthesia to fatal respiratory arrest, with only a small margin between them, and the margin narrows with tolerance and with any other depressant. There is no ceiling effect and no antidote. It must never be stopped abruptly after regular use.
Dose ranges
≈100 mg at bedtime (adult)
IV loading + infusion, specialist-titrated to EEG
Duration
Oral ≈15–60 min, IV within minutes
Hypnotic effect ≈3–6 h (elimination half-life ≈15–48 h)
Residual sedation/'hangover'. Withdrawal on cessation after regular use
Chemical & Physical Properties
| Formula | C11H18N2O3 |
| Molar mass | 226.27 g/mol |
| State | Solid |
| Melting point | 129.5 °C |
| Boiling point | Not reported |
| Density | Not reported |
| Vapor pressure | Not reported |
| pKa | 8.11 (25 °C) |
| LogP | 2.1 |
| Solubility | 679 mg/L (at 25 °C), Pentobarbital sodium: a white, hygroscopic, crystalline powder or granules, odourless or with a slight characteristic odour and a slightly bitter taste. Very soluble in water and alcohol. Practically insoluble in ether. A 10% solution in water has pH 9.6–11 and slowly decomposes., Pentobarbital calcium: a fine, white, odourless, crystalline powder with a slightly bitter taste. Sparingly soluble in water. Slightly soluble in alcohol. Practically insoluble in ether. A saturated solution in water has pH about 9.5. |
| Refractive index | Not reported |
Identifiers & Synonyms
| CAS | 76-74-4 |
| CAS (enantiomer) | |
| PubChem CID | 4737 |
| InChIKey | WEXRUCMBJFQVBZ-UHFFFAOYSA-N |
| InChI | InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16) |
| SMILES | CCCC(C)C1(C(=O)NC(=O)NC1=O)CC |
Synonyms
Pharmacodynamics & Biochemistry
Pentobarbital (Nembutal) is a short-to-intermediate-acting barbiturate. It is a positive allosteric modulator of the GABA-A receptor: it binds the barbiturate site and increases the duration of chloride-channel opening in response to GABA, and at higher concentrations it opens the channel directly, independent of GABA. This direct action is why barbiturates, unlike benzodiazepines, have no ceiling to their sedative and respiratory depression: the basis of both their anaesthetic use and their lethality. Its effects run along a dose continuum from anxiolysis and sedation through hypnosis to general anaesthesia, coma and death. It is well absorbed orally (bioavailability ≈70–90%) and metabolised in the liver, with a half-life of roughly 15–48 hours. Onset is faster and duration shorter than phenobarbital's. Because a controlled, reliably lethal dose produces deep coma and painless respiratory arrest, pentobarbital sodium is the agent of choice for animal euthanasia and is widely used in physician-assisted dying and in capital-punishment lethal injection. In intensive care a 'pentobarbital coma' is used to control refractory status epilepticus and dangerously raised intracranial pressure.
Biological targets
- GABA-A
Binding & functional measurements
Pharmacokinetics
| Bioavailability | Oral ≈70–90% (rectal ≈90%) |
| Tmax | Not reported |
| Half-life | ≈15–48 h |
| Vd | Not reported |
| Protein binding | ≈20–45% |
| Metabolism | Hepatic |
| Excretion | Renal |
Toxicology & Safety
Not reported
Pentobarbital has a low therapeutic index and no ceiling on respiratory depression, so the difference between a sedative, an anaesthetic and a fatal dose is small. It causes death by respiratory arrest, and indeed it is used deliberately for euthanasia and lethal injection. The danger is multiplied by alcohol, opioids and benzodiazepines. There is no specific antidote (flumazenil does not reverse barbiturates). Overdose care is supportive (airway/ventilatory and circulatory support). Regular use produces tolerance and physical dependence, and abrupt withdrawal is dangerous: a syndrome like severe alcohol/benzodiazepine withdrawal with agitation, tremor, seizures and delirium that can be fatal and requires a slow taper. Never use non-medically.[2]
Legal Status
US: Schedule II. UK: Class B (Schedule 3). DE: BtMG Anlage III
Interactions & Contraindications
Drug interactions
Contraindications
No interactions or contraindications listed.
Usage & Context
- A short/intermediate-acting barbiturate (Nembutal) once widely used as a sedative and sleeping pill, now largely replaced by benzodiazepines for that purpose.
- Current uses are mostly at the extremes: control of refractory status epilepticus and raised intracranial pressure ('pentobarbital coma') in intensive care, and, as pentobarbital sodium, veterinary euthanasia, physician-assisted dying and capital-punishment lethal injection.
- Diverted 'Nembutal' is also sought illicitly, notably for suicide.
Sources & Evidence
- PubChem: Pentobarbital (CID 4737) — identifiers & experimental properties
- Wikipedia: Pentobarbital — GABA-A mechanism, uses (euthanasia/assisted dying/ICU coma), pharmacokinetics, toxicity & legal status CC BY-SA 4.0
- DEA Diversion Control Division: Controlled Substance Schedules (pentobarbital is Schedule II)
- GOV.UK: Controlled drugs list — pentobarbital is Class B / Schedule 3 (Misuse of Drugs legislation) OGL v3.0
- BtMG Anlage III — Pentobarbital (gesetze-im-internet.de)